Toto R D, Mitchell H C, Smith R D, Lee H C, McIntire D, Pettinger W A
Department of Internal Medidcine and Biostatistics, University of Texas Southwestern Medical Center-Dallas, USA.
Kidney Int. 1995 Sep;48(3):851-9. doi: 10.1038/ki.1995.361.
Hypertensive nephrosclerosis is a progressive renal disease and the leading cause of end-stage renal disease (ESRD) in blacks in the United States. It is generally believed that hypertensive renal injury is responsible for progressive renal failure; however, it is not known whether pharmacologic lowering of blood pressure to any level prevents progression of renal disease. Accordingly, we performed a long-term prospective randomized trial to determine whether "strict" [diastolic blood pressure (DBP) 65 to 80 mm Hg] versus "conventional" (DBP 85 to 95 mm Hg) blood pressure control is associated with a slower rate of decline in glomerular filtration rate. Eighty-seven non-diabetic patients (age 25 to 73; 68 black, 58 male) with long-standing hypertension (DBP > or = 95 mm Hg), chronic renal insufficiency (GFR < or = 70 m/min/1.73 m2) and a normal urine sediment were studied. DBP was pharmacologically lowered to < or = 80 mm Hg (3 of 4 consecutive measurements at 1 to 4 weeks intervals) after which patients were randomized. DBP and GFR (renal clearance of 125I-iothalamate) were measured at baseline, at three months and every six months post-randomization. The rate of decline in GFR (GFR slope, in ml/min/1.73 m2/year), estimated by the method of maximum likelihood in a mixed effects model, was the primary outcome variable. In a secondary analysis, 50% reduction in GFR (or a doubling of serum creatinine) from baseline, ESRD and death were combined.(ABSTRACT TRUNCATED AT 250 WORDS)
高血压性肾硬化是一种进行性肾脏疾病,是美国黑人终末期肾病(ESRD)的主要病因。一般认为,高血压性肾损伤是导致进行性肾衰竭的原因;然而,尚不清楚将血压药物性降低到任何水平是否能阻止肾病进展。因此,我们进行了一项长期前瞻性随机试验,以确定“严格”(舒张压65至80毫米汞柱)与“常规”(舒张压85至95毫米汞柱)血压控制是否与肾小球滤过率下降速度较慢相关。研究了87例非糖尿病患者(年龄25至73岁;68例黑人,58例男性),他们患有长期高血压(舒张压≥95毫米汞柱)、慢性肾功能不全(肾小球滤过率≤70毫升/分钟/1.73平方米)且尿沉渣正常。通过药物将舒张压降低至≤80毫米汞柱(每隔1至4周连续测量4次中有3次达到该水平),之后将患者随机分组。在基线、随机分组后3个月及每6个月测量舒张压和肾小球滤过率(125I-碘肽酸盐的肾清除率)。在混合效应模型中采用最大似然法估计的肾小球滤过率下降速度(肾小球滤过率斜率,单位为毫升/分钟/1.73平方米/年)是主要结局变量。在一项次要分析中,将肾小球滤过率较基线降低50%(或血清肌酐翻倍)、终末期肾病和死亡合并计算。(摘要截短至250字)